Hello and welcome

Amyloidosis is a group of complex, incurable diseases which are frequently misdiagnosed and under-recognised.

The AAN is an amalgamation of four multi-disciplinary medical amyloidosis centres, dedicated to the diagnosis and management of Australian patients with all types of amyloidosis.

This website has been developed by the AAN as a practical resource for Australian patients, carers and their doctors, to enhance awareness and ensure the timely and correct diagnosis of their type of amyloidosis.

find out more about us >

Amyloidosis Centres operate in Sydney, Brisbane, Melbourne and Perth.
Find a location nearest to you.

contact us >

Here to help

Click through to our tailored portals to find information and resources for patients & carers or health professionals

Patients & Carers
Health Professionals
TAFAMIDIS Capsule 61 mg Vyndamax® Pfizer Australia Pty Ltd, Resubmission to request an Authority Required listing for the treatment of ATTR-CM. Not recommended by the PBAC    The PBAC has recommended daratumumab subcutaneous(SC) for use in combination with CyBorD for treatment of patients with newly diagnosed systemic AL amyloidosis .    2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis:    Darzalex/daratumumab to treat AL amyloidosis, now listed on the PBS   Alnylam Reports Positive Topline Results for APOLLO-B Phase 3 Study on Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy    A Note of Caution re VRD in AL amyloidosis    Coronavirus (COVID-19) Official Australian Government Information

Patient Experiences

News

View all News

Upcoming Events

View Calendar